Intersecting Anemias: PARP Inhibitor-Induced Toxicity and Autoimmune Hemolysis-A Case Report.

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• A 71-year-old woman with high-grade serous ovarian adenocarcinoma received neoadjuvant and adjuvant chemotherapy, followed by maintenance therapy with bevacizumab and olaparib.
• Neurological complications led to bevacizumab discontinuation, after which the patient developed severe, progressive anemia (hemoglobin as low as 54 g/L).

Purpose of the Study:

• To investigate the complex etiology of severe anemia in a patient undergoing ovarian cancer treatment.
• To highlight the challenges in managing drug-induced hematologic toxicity and overlapping conditions.

Main Methods:

• The patient's treatment history, including chemotherapy, surgery, and maintenance therapy with bevacizumab and olaparib, was reviewed.
• Diagnostic workup included ruling out common anemia causes, bone marrow biopsies, and assessment for autoantibodies.
• Treatment response to high-dose corticosteroids was evaluated.

Main Results:

• Bone marrow biopsies revealed a clonal cytotoxic T-LGL population and a DNMT3A mutation, with no evidence of myelodysplasia or metastasis.
• The patient developed warm autoantibodies (IgG) and a decline in reticulocytes, indicating a mixed anemia profile.
• High-dose corticosteroids induced rapid hematological improvement, resolving transfusion dependence.

Conclusions:

• The severe anemia was likely of mixed origin, involving hypo-regenerative components from prolonged PARP inhibitor (olaparib) toxicity and a hemolytic mechanism due to warm autoantibodies.
• Confounding factors including a DNMT3A mutation and T-LGL clone complicated the diagnosis and management.
• This case underscores the importance of comprehensive hematological assessment in managing complex drug-induced toxicities and overlapping conditions in cancer patients.